Benjamin Hohl, the Chief Financial Officer of Enliven Therapeutics, Inc. (NASDAQ:ELVN), a biotechnology company with a market capitalization of $1.07 billion, recently executed a series of stock ...

根据提交给美国证券交易委员会的Form 4文件显示，市值10.7亿美元的生物科技公司Enliven Therapeutics, Inc. (NASDAQ: ELVN )首席财务官Benjamin Hohl近期进行了一系列股票交易。根据InvestingPro数据，该公司整体财务健康状况评级为"良好"。2月5日，Hohl以平均价格22.52美元出售了1,000股普通股，总售价为22,524美元。

announced new analyses of data from the Phase 2b ENLIVEN trial evaluating pegozafe SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage ...

E-Mini Nasdaq 100 21575.25-296.50-1.36% ...

Electronic Arts Inc. $128.60-3.40-2.58% ...

2-Year U.S. Treasury Note Continuous Contract $102.691-0.172-0.17% 5-Year U.S. Treasury Note Continuous Contract $106.391-0.344-0.32% 10-Year U.S. Treasury Note Continuous Contract $109.156-0.422 ...

In early trading on Monday, shares of Idexx Laboratories, topped the list of the day's best performing components of the Nasdaq 100 index, trading up 10.3%. Year to date, Idexx Laboratories ...

The S&P 500 and the Nasdaq rose on Thursday, as investors sifted through several upbeat earnings reports while awaiting Friday's key jobs report and any trade policy moves.

US stocks were mixed on Thursday in anticipation of Amazon's (AMZN) quarterly results, as investors assessed the earnings season so far and eyed President Donald Trump's fast-moving policy ...

Fund manager updated portfolio less frequently than peers in last 1 year. (I.e. fund manager held stocks/bonds in the portfolio for longer duration than peers) ...